The sixty human tumor cell line anticancer screening data at single dose assay (10−5 M concentration) as percent cell inhibition of compounds XIII, XIV, XV & XVIa.
| Cell line | Compound no. | |||
|---|---|---|---|---|
| XIII | XIV | XV | XVI | |
| Leukemia | ||||
| CCRF-CEM | 4.35 | 14.88 | −3.11 | NT |
| HL-60(TB) | 3.30 | 10.45 | 1.88 | 145.54 |
| K-562 | 2.63 | 25.34 | −0.25 | 89.44 |
| MOLT-4 | 0.73 | 11.59 | −7.57 | 96.27 |
| RPMI-8226 | 3.55 | 24.02 | 0.80 | 116.64 |
| SR | 6.80 | 26.04 | 4.74 | 128.89 |
| Non-small cell lung cancer | ||||
| A549/ATCC | −9.39 | −5.50 | −6.49 | 132.54 |
| EKVX | 12.37 | 17.80 | 5.12 | 144.79 |
| HOP-62 | −2.98 | −3.48 | 5.00 | 152.69 |
| HOP-92 | −6.68 | 4.35 | 4.93 | 170.93 |
| NCI-H226 | 11.49 | 32.35 | 17.11 | 56.09 |
| NCI-H23 | NT | NT | NT | 155.11 |
| NCI-H322M | 69.30 | 10.33 | 1.59 | 15.17 |
| NCI-H460 | 65.00 | 3.85 | −6.06 | 122.10 |
| NCI-H522 | −6.93 | 20.20 | 10.84 | 179.35 |
| Colon cancer | ||||
| COLO 205 | 97.35 | −4.70 | −7.70 | 150.21 |
| HCC-2998 | 86.37 | −6.65 | −3.24 | 40.29 |
| HCT-116 | 58.65 | 8.74 | −9.85 | 91.77 |
| HCT-15 | 72.94 | 2.34 | −11.65 | 130.72 |
| HT29 | 83.52 | −1.02 | −4.77 | 161.53 |
| KM12 | 40.60 | 9.07 | 2.76 | 95.45 |
| SW-620 | 81.53 | 3.20 | −1.88 | 123.86 |
| CNS cancer | ||||
| SF-268 | 73.30 | 8.83 | 6.94 | 134.37 |
| SF-295 | 46.58 | −11.73 | −9.76 | 131.40 |
| SF-539 | 59.89 | 2.29 | −3.61 | 188.20 |
| SNB-19 | 88.90 | 1.89 | −1.52 | 41.60 |
| SNB-75 | 53.50 | −8.62 | 19.30 | 174.96 |
| U251 | 87.14 | 2.45 | −0.28 | 172.52 |
| Melanoma | ||||
| LOX IMVI | 53.82 | 21.59 | 11.67 | 187.39 |
| MALME-3M | 72.76 | 0.21 | −10.37 | 167.26 |
| M14 | 62.16 | 3.99 | −5.15 | 95.18 |
| MDA-MB-435 | 58.98 | 3.15 | −3.11 | 92.86 |
| SK-MEL-2 | 46.66 | 8.32 | −5.97 | 72.03 |
| SK-MEL-28 | 59.00 | 4.21 | −4.39 | 27.65 |
| SK-MEL-5 | 37.50 | 27.16 | 5.86 | 70.64 |
| UACC-257 | 66.91 | −3.73 | −10.30 | 45.74 |
| UACC-62 | 34.57 | 18.17 | 3.34 | 82.55 |
| Ovarian cancer | ||||
| IGROV1 | 59.41 | 10.34 | 49.06 | 141.81 |
| OVCAR-3 | 94.00 | 12.46 | −5.47 | 155.56 |
| OVCAR-4 | 51.61 | 8.69 | 0.64 | 86.42 |
| OVCAR-5 | 83.82 | 3.43 | −1.45 | 104.09 |
| OVCAR-8 | 65.24 | 5.72 | 0.41 | 121.38 |
| NCI/ADR-RES | 60.62 | 8.96 | −0.12 | 132.63 |
| SK-OV-3 | 67.09 | 1.90 | −10.10 | 71.86 |
| Renal cancer | ||||
| 786-0 | 80.79 | 0.36 | 5.63 | 180.94 |
| A498 | 107.50 | −4.72 | 3.13 | 51.04 |
| ACHN | 45.35 | 20.47 | 9.38 | 187.46 |
| CAKI-1 | 47.75 | 21.68 | 28.23 | 195.69 |
| RXF 393 | 76.34 | 4.44 | −10.84 | 171.34 |
| SN12C | 76.90 | 17.97 | 3.48 | 154.68 |
| TK-10 | 93.85 | −34.09 | −15.74 | 156.49 |
| UO-31 | 34.26 | 45.53 | 31.93 | 197.16 |
| Prostate cancer | ||||
| PC-3 | 70.01 | 19.04 | 10.97 | 136.14 |
| DU-145 | 75.39 | −1.94 | −5.36 | 196.08 |
| Breast cancer | ||||
| MCF7 | 45.57 | 27.53 | 16.49 | 83.90 |
| MDA-MB-231/ATCC | 64.96 | 6.69 | −0.80 | 70.26 |
| HS 578T | 60.40 | 12.15 | 9.50 | 96.08 |
| BT-549 | 76.87 | 13.66 | 0.30 | 185.88 |
| T-47D | 33.57 | 30.68 | 20.07 | 72.12 |
| MDA-MB-468 | 35.78 | 31.66 | 2.52 | 139.82 |
| Mean | 94.47 | 90.78 | 97.85 | −23.26 |
a
NT, not tested.